A Holistic & Innovative Approach

The prevalence and cost of cardiometabolic conditions is the healthcare problem of our generation. The Rimidi platform is designed to holistically support the complexity of treating multiple, comorbid conditions, enabling clinicians to seamlessly switch between views with condition-specific data for individual patients and populations.

Diabetes

By combining patient-generated data from devices like glucometers, CGMs, and blood pressure cuffs with relevant data from the EHR, Rimidi gives clinicians a more complete view of their patients' health, helping drive better, patient-specific clinical decisions.

Request Demo Learn More

Heart Failure

With growing pressure on health systems to keep patients healthy at home due to cost and frequency of readmission, Rimidi provides a cost-effective, easy-to-use tech solution for virtual management of heart failure patients.

Request Demo Learn More

Fatty Liver Disease

The most common form of liver disease around the world, Nonalcoholic Fatty Liver Disease (NAFLD) and its most aggressive form, Nonalcoholic Steatohepatitis (NASH) are not well-known among the general population, but their comorbid conditions like diabetes, obesity, and metabolic syndrome are. Rimidi’s NAFLD and NASH platform view supports the complexity of engaging and managing your population at risk for NAFLD and NASH – all while working within your EHR.

Request Demo Learn More

Cardiovascular Disease

With the rapid rise of cardiovascular disease, the cost for treatment in coming years will be staggering. Armed with better data, clinicians can risk stratify their patients, remotely monitor their progress, and intervene with timely, guideline-based management—all helping to reduce the staggering cost attached to the condition.

Request Demo Learn More

Obesity

Obesity is a global epidemic in both children and adults, and is one of the biggest contributors to preventable chronic disease and rising US healthcare costs. Rimidi’s obesity view alerts clinicians to risk factors associated with obesity (e.g. hypertension, type 2 diabetes, nonalcoholic fatty liver disease), and identifies and closes gaps in best practices in obesity management.

Request Demo Learn More